What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Nicholas J. Vogelzang mostly deals with Internal medicine, Surgery, Oncology, Prostate cancer and Cancer.
His Internal medicine research integrates issues from Gastroenterology and Endocrinology.
His Surgery research includes elements of Placebo, Carcinoma and Mesothelioma.
His Oncology research incorporates themes from Combination chemotherapy, Randomized controlled trial, Pathology, Proportional hazards model and Metastasis.
The various areas that Nicholas J. Vogelzang examines in his Prostate cancer study include Hazard ratio, Prostate, Docetaxel and Urology.
His study looks at the relationship between Chemotherapy and fields such as Atezolizumab, as well as how they intersect with chemical problems.
His most cited work include:
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma (2205 citations)
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer (1817 citations)
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer (1700 citations)
What are the main themes of his work throughout his whole career to date?
Nicholas J. Vogelzang spends much of his time researching Internal medicine, Oncology, Prostate cancer, Surgery and Chemotherapy.
His Internal medicine study deals with Gastroenterology intersecting with Adverse effect.
His work in Oncology addresses subjects such as Sipuleucel-T, which are connected to disciplines such as Asymptomatic.
As a part of the same scientific study, Nicholas J. Vogelzang usually deals with the Prostate cancer, concentrating on Urology and frequently concerns with Endocrinology.
His studies in Surgery integrate themes in fields like Mesothelioma and Hazard ratio.
As part of one scientific family, Nicholas J. Vogelzang deals mainly with the area of Chemotherapy, narrowing it down to issues related to the Toxicity, and often Pharmacology.
He most often published in these fields:
- Internal medicine (69.21%)
- Oncology (50.61%)
- Prostate cancer (31.25%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (69.21%)
- Oncology (50.61%)
- Prostate cancer (31.25%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Oncology, Prostate cancer, In patient and Cancer research.
His study in Docetaxel, Adverse effect, Clinical trial, Chemotherapy and Renal cell carcinoma falls within the category of Internal medicine.
His research investigates the link between Adverse effect and topics such as Gastroenterology that cross with problems in Placebo.
Bladder cancer, Hazard ratio and Mesothelioma is closely connected to Randomized controlled trial in his research, which is encompassed under the umbrella topic of Clinical trial.
His Oncology research is multidisciplinary, incorporating elements of Pembrolizumab, Urothelial cancer, Circulating tumor cell and Phases of clinical research.
Nicholas J. Vogelzang combines subjects such as Rucaparib and Asymptomatic with his study of Prostate cancer.
Between 2017 and 2021, his most popular works were:
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial (243 citations)
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. (150 citations)
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. (102 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Internal medicine, Prostate cancer, Oncology, Cancer research and Docetaxel are his primary areas of study.
His study in Internal medicine focuses on Adverse effect, Clinical endpoint, Chemotherapy, Atezolizumab and Clear cell renal cell carcinoma.
His Adverse effect research incorporates elements of Gastroenterology and Carcinoma.
His study in Prostate cancer is interdisciplinary in nature, drawing from both Survival rate, Circulating tumor cell and Hazard ratio.
The study incorporates disciplines such as Pembrolizumab, Regimen, Clinical trial and Asymptomatic in addition to Oncology.
His work deals with themes such as Androgen and Urology, which intersect with Clinical trial.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
